Quadrature Capital
PHAT icon

Quadrature Capital’s Phathom Pharmaceuticals PHAT Stock Holding History

Quadrature Capital’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,078
Closed -$134K – 1950
2026
Q1 		$134K Buy
+12,078
New +$153K ﹤0.01% 1184
2025
Q4 		– Sell
-30,272
Closed -$356K – 1568
2025
Q3 		$356K Buy
+30,272
New +$312K ﹤0.01% 624

Other funds holding PHAT

Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Quadrature Capital's PHAT Position: Q2 2026 in Review

Quadrature Capital sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 12,078 shares — an estimated $134K sold.

Quadrature Capital first reported a position in PHAT in Q3 2025 and held it in 2 quarters. The position peaked at $356K in Q3 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Quadrature Capital reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 12,078 Phathom Pharmaceuticals shares in Q2 2026, an estimated $134K.
  • Quadrature Capital first reported a position in Phathom Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Quadrature Capital's Phathom Pharmaceuticals position peaked at $356K in Q3 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.